Contact
    Start Publications Exploring the Toxicity, Lung Distribution, and Cellular Uptake ...
    ←  Publication Finder
    KSV NIMA

    Exploring the Toxicity, Lung Distribution, and Cellular Uptake of Rifampicin and Ascorbic Acid-Loaded Alginate Nanoparticles as Therapeutic Treatment of Lung Intracellular Infections

    Year: 2021

    Journal: Mol. Pharm., Volume 18, MAR 1, page 807–821

    Authors: Scolari, IR; Volpini, X; Fanani, ML; De La Cruz-Thea, B; Natali, L; Musri, MM; Granero, GE

    Organizations: Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Secretaria de Ciencia y Tecnica de la Universidad Nacional de Cordoba (SECyT-UNC)Secretaria de Ciencia y Tecnologia (SECYT); Fondo para la Investigacion Cientifica y Tecnologica (FONCYT)FONCyT

    Keywords: rifampicin; ascorbic acid; nanoparticles; intratracheal administration; cytotoxicity; respiratory barriers

    Nanotechnology is a very promising technological tool to combat health problems associated with the loss of effectiveness of currently used antibiotics. Previously, we developed a formulation consisting of a chitosan and tween 80-decorated alginate nanocarrier that encapsulates rifampicin and the antioxidant ascorbic acid (RIF/ASC), intended for the treatment of respiratory intracellular infections. Here, we investigated the effects of RIF/ASC-loaded NPs on the respiratory mucus and the pulmonary surfactant. In addition, we evaluated their cytotoxicity for lung cells in vitro, and their biodistribution on rat lungs in vivo after their intratracheal administration. Findings herein demonstrated that RIF/ASC-loaded NPs display a favorable lung biocompatibility profile and a uniform distribution throughout lung lobules. RIF/ASC-loaded NPs were mainly uptaken by lung macrophages, their primary target. In summary, findings show that our novel designed RIF/ASC NPs could be a suitable system for antibiotic lung administration with promising perspectives for the treatment of pulmonary intracellular infections.
    View publication